Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging

Linda K. Mooberry, Nirupama A. Sabnis, Marlyn Panchoo, Bhavani Nagarajan, Andras G. Lacko

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently overexpressed by most tumor cells. Scavenger Receptor Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation of cancer cells and thus a potential major impact in carcinogenesis and metastasis. Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer. Moreover, genomic data show that depending on the type of cancer, high or low SR-BI expression may promote poor survival. This review discusses the importance of SR-BI as a diagnostic as well as prognostic indicator of cancer to help elucidate the contributions of this protein to cancer development, progression, and survival. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.

Original languageEnglish
Article number466
JournalFrontiers in Pharmacology
Volume7
Issue numberDEC
DOIs
StatePublished - 1 Jan 2016

Fingerprint

Scavenger Receptors
CD36 Antigens
Neoplasms
Therapeutics
Cholesterol Esters
HDL Lipoproteins
Nanoparticles
Lipoproteins
Prostatic Neoplasms
Carcinogenesis
Cholesterol
Cell Proliferation
Breast Neoplasms
Neoplasm Metastasis
Technology

Keywords

  • Drug Delivery Systems
  • Gateway for theranostics
  • Individual therapy
  • SR-B1
  • Tumor imaging

Cite this

Mooberry, Linda K. ; Sabnis, Nirupama A. ; Panchoo, Marlyn ; Nagarajan, Bhavani ; Lacko, Andras G. / Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging. In: Frontiers in Pharmacology. 2016 ; Vol. 7, No. DEC.
@article{65fe519cfd0b4c39a39f439424107689,
title = "Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging",
abstract = "Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently overexpressed by most tumor cells. Scavenger Receptor Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation of cancer cells and thus a potential major impact in carcinogenesis and metastasis. Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer. Moreover, genomic data show that depending on the type of cancer, high or low SR-BI expression may promote poor survival. This review discusses the importance of SR-BI as a diagnostic as well as prognostic indicator of cancer to help elucidate the contributions of this protein to cancer development, progression, and survival. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.",
keywords = "Drug Delivery Systems, Gateway for theranostics, Individual therapy, SR-B1, Tumor imaging",
author = "Mooberry, {Linda K.} and Sabnis, {Nirupama A.} and Marlyn Panchoo and Bhavani Nagarajan and Lacko, {Andras G.}",
year = "2016",
month = "1",
day = "1",
doi = "10.3389/fphar.2016.00466",
language = "English",
volume = "7",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "DEC",

}

Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging. / Mooberry, Linda K.; Sabnis, Nirupama A.; Panchoo, Marlyn; Nagarajan, Bhavani; Lacko, Andras G.

In: Frontiers in Pharmacology, Vol. 7, No. DEC, 466, 01.01.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging

AU - Mooberry, Linda K.

AU - Sabnis, Nirupama A.

AU - Panchoo, Marlyn

AU - Nagarajan, Bhavani

AU - Lacko, Andras G.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently overexpressed by most tumor cells. Scavenger Receptor Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation of cancer cells and thus a potential major impact in carcinogenesis and metastasis. Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer. Moreover, genomic data show that depending on the type of cancer, high or low SR-BI expression may promote poor survival. This review discusses the importance of SR-BI as a diagnostic as well as prognostic indicator of cancer to help elucidate the contributions of this protein to cancer development, progression, and survival. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.

AB - Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently overexpressed by most tumor cells. Scavenger Receptor Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation of cancer cells and thus a potential major impact in carcinogenesis and metastasis. Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer. Moreover, genomic data show that depending on the type of cancer, high or low SR-BI expression may promote poor survival. This review discusses the importance of SR-BI as a diagnostic as well as prognostic indicator of cancer to help elucidate the contributions of this protein to cancer development, progression, and survival. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.

KW - Drug Delivery Systems

KW - Gateway for theranostics

KW - Individual therapy

KW - SR-B1

KW - Tumor imaging

UR - http://www.scopus.com/inward/record.url?scp=85009165968&partnerID=8YFLogxK

U2 - 10.3389/fphar.2016.00466

DO - 10.3389/fphar.2016.00466

M3 - Review article

AN - SCOPUS:85009165968

VL - 7

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - DEC

M1 - 466

ER -